IN2012DN02210A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02210A
IN2012DN02210A IN2210DEN2012A IN2012DN02210A IN 2012DN02210 A IN2012DN02210 A IN 2012DN02210A IN 2210DEN2012 A IN2210DEN2012 A IN 2210DEN2012A IN 2012DN02210 A IN2012DN02210 A IN 2012DN02210A
Authority
IN
India
Prior art keywords
patient
methods
neurotoxin
prolongation
presented
Prior art date
Application number
Other languages
English (en)
Inventor
M Gaxiola Gustavo
E Aguilar Ivan
P Paz Gilberto
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IN2012DN02210A publication Critical patent/IN2012DN02210A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN2210DEN2012 2009-08-26 2010-08-10 IN2012DN02210A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/548,073 US8147848B2 (en) 2009-08-26 2009-08-26 Method for treating premature ejaculation with a botulinum neurotoxin
PCT/US2010/044959 WO2011028371A1 (en) 2009-08-26 2010-08-10 Methods of treating chronic neurogenic inflammation using a modified clostridial toxin

Publications (1)

Publication Number Publication Date
IN2012DN02210A true IN2012DN02210A (enExample) 2015-08-21

Family

ID=43127150

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2210DEN2012 IN2012DN02210A (enExample) 2009-08-26 2010-08-10

Country Status (18)

Country Link
US (8) US8147848B2 (enExample)
EP (2) EP2708239B1 (enExample)
JP (2) JP5766699B2 (enExample)
KR (1) KR101612988B1 (enExample)
CN (2) CN103816530B (enExample)
AU (2) AU2010289969B2 (enExample)
BR (1) BR112012004246A2 (enExample)
CA (1) CA2772372C (enExample)
CY (1) CY1114792T1 (enExample)
DK (2) DK2708239T3 (enExample)
ES (2) ES2446969T3 (enExample)
IN (1) IN2012DN02210A (enExample)
MX (2) MX2012002378A (enExample)
PL (1) PL2470202T3 (enExample)
PT (1) PT2470202E (enExample)
RU (1) RU2568844C2 (enExample)
SI (1) SI2470202T1 (enExample)
WO (1) WO2011028371A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
US20120251518A1 (en) * 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
US20130066148A1 (en) * 2011-09-12 2013-03-14 Kang Seon Cho Method of augmenting glans
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
CN104321048B (zh) 2012-04-13 2019-01-11 路博润高级材料公司 抑制神经元胞吐的化合物(ii)
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
US9764010B2 (en) * 2012-08-24 2017-09-19 Allergan, Inc. Method for treating premature ejaculation with a neurotoxin
CN107205889B (zh) * 2014-09-02 2021-05-11 美国白银有限责任公司 肉毒毒素和胶体银颗粒
RU2565104C1 (ru) * 2014-10-24 2015-10-20 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздрава России) Способ лечения преждевременной эякуляции
RU2019141383A (ru) * 2017-05-18 2021-06-18 Реванс Терапьютикс, Инк. (Revance Therapeutics, Inc.) Способы лечения цервикальной дистонии
WO2018220232A1 (en) * 2017-06-02 2018-12-06 Universite De Versailles-St Quentin En Yvelines Pharmaceutical combination product comprising botulinum toxin for the treatment of erectile dysfunction
US12102556B2 (en) 2022-05-31 2024-10-01 Max Azevedo System and method for fallopian birth control
US12337014B1 (en) 2024-06-17 2025-06-24 Enrico Guarino Intracavernosal gel infusion system with neurotoxin modulation for erectile function

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9120306D0 (en) 1991-09-24 1991-11-06 Graham Herbert K Method and compositions for the treatment of cerebral palsy
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US5427291A (en) 1993-09-21 1995-06-27 Smith; David S. Ski carrier and method employing same
DE69434610T2 (de) 1993-12-28 2008-11-27 Allergan, Inc., Irvine Verwendung der neurotoxischen Komponente des Botulinum Toxins zur Behandlung von Muskelspasmen
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
CN1123680A (zh) * 1994-11-18 1996-06-05 吕建京 一种对于肺脾肾虚有良好功效的保健品及其制造方法
EP1502601B2 (en) 1997-07-15 2010-07-21 The Regents of the University of Colorado Use of neurotoxin therapy for treatment of urinary retention
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6593335B1 (en) 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
CN1146866C (zh) * 1998-11-17 2004-04-21 阿尔卑斯电气株式会社 浮起式磁头的冠顶形成方法及冠顶形成装置
FR2793689B1 (fr) 1999-05-19 2001-08-24 Pf Medicament Dispositif transdermique pour l'administration de testosterone ou d'un de ses derives
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
RU2180591C2 (ru) * 1999-12-24 2002-03-20 Государственное научное предприятие Московский научно-исследовательский институт психиатрии МЗ РФ Средство для лечения сексуальных дисфункций у мужчин
US6495154B1 (en) 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
US20020086036A1 (en) 2000-12-05 2002-07-04 Allergan Sales, Inc. Methods for treating hyperhidrosis
US6974839B2 (en) 2001-03-16 2005-12-13 Dmi Biosciences, Inc. Method of delaying ejaculation
PL364580A1 (en) 2001-03-29 2004-12-13 Bristol-Myers Squibb Company Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
US20030113349A1 (en) 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
WO2003063776A2 (en) * 2002-01-25 2003-08-07 Modular Properties Ltd Methods and compositions for treating male erectile dysfunction
US6776991B2 (en) 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US20040009180A1 (en) 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
TW200418838A (en) 2002-09-18 2004-10-01 Bristol Myers Squibb Co Compounds for the treatment of premature ejaculation
US20070264373A1 (en) * 2004-01-26 2007-11-15 Ian Carroll Toxin Induced Sympathectomy
US20060100584A1 (en) 2004-08-10 2006-05-11 Orest Olejnik Needleless microprotrusion elastoplast system
US20080220021A1 (en) 2005-02-14 2008-09-11 Pankaj Modi Topical Botulinum Toxin Compositions for the Treatment of Hyperhidrosis
CN1682810A (zh) * 2005-02-22 2005-10-19 黄资源 一种治疗前列腺疾病的前列外敷散
JP2008531732A (ja) 2005-03-03 2008-08-14 ルバンス セラピュティックス インク． ボツリヌス毒素の局所塗布及び経皮送達のための組成物及び方法
CN103126971A (zh) 2005-11-17 2013-06-05 雷文斯治疗公司 减少非毒素蛋白质的肉毒杆菌毒素组合物和其局部施用及透皮递送方法
US7445783B2 (en) 2006-10-30 2008-11-04 Cappellos, Inc. Topical and transdermal treatments using urea formulations
JP2010528981A (ja) 2006-12-01 2010-08-26 アンテリオス， インコーポレイテッド 両親媒性実体ナノ粒子
US20090005319A1 (en) * 2007-07-01 2009-01-01 Barone Jr Frank V Topical compositions for delaying ejaculation and methods of using the same
US20090093547A1 (en) * 2007-10-09 2009-04-09 Sciele Pharma, Inc. Compositions and Methods for Treating Premature Ejaculation
RU2010120016A (ru) 2007-10-23 2011-11-27 Аллерган, Инк. (Us) Способы лечения хронического нейрогенного воспаления с применением модифицированных клостридиальных токсинов
US8147848B2 (en) 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
US9049616B2 (en) 2012-03-29 2015-06-02 Broadcom Corporation Session recovery after network coordinator or AP restart for single user, multiple user, multiple access, and/or MIMO wireless communications
US9764010B2 (en) 2012-08-24 2017-09-19 Allergan, Inc. Method for treating premature ejaculation with a neurotoxin

Also Published As

Publication number Publication date
HK1194292A1 (en) 2014-10-17
US20110052636A1 (en) 2011-03-03
US20160067319A1 (en) 2016-03-10
US8617570B2 (en) 2013-12-31
JP6078108B2 (ja) 2017-02-08
ES2446969T3 (es) 2014-03-11
WO2011028371A1 (en) 2011-03-10
US20140140981A1 (en) 2014-05-22
DK2708239T3 (en) 2016-03-14
US10420823B2 (en) 2019-09-24
HK1171658A1 (en) 2013-04-05
JP2013503165A (ja) 2013-01-31
US8916177B2 (en) 2014-12-23
US8329193B2 (en) 2012-12-11
MX2012002378A (es) 2012-06-28
US20150064167A1 (en) 2015-03-05
MX349947B (es) 2017-08-22
RU2568844C2 (ru) 2015-11-20
KR101612988B1 (ko) 2016-04-15
JP2015163654A (ja) 2015-09-10
CA2772372C (en) 2016-07-12
US20130059789A1 (en) 2013-03-07
US20180185460A1 (en) 2018-07-05
KR20120103760A (ko) 2012-09-19
EP2708239B1 (en) 2015-12-09
AU2010289969B2 (en) 2015-05-14
JP5766699B2 (ja) 2015-08-19
CN102802663A (zh) 2012-11-28
AU2015213381A1 (en) 2015-09-03
CN103816530B (zh) 2016-12-07
BR112012004246A2 (pt) 2016-04-05
CA2772372A1 (en) 2011-03-10
PL2470202T3 (pl) 2014-05-30
CN102802663B (zh) 2014-03-19
US9186395B2 (en) 2015-11-17
PT2470202E (pt) 2014-02-24
EP2470202B1 (en) 2013-12-18
US8147848B2 (en) 2012-04-03
AU2015213381B2 (en) 2017-05-25
US20170020997A1 (en) 2017-01-26
US9907841B2 (en) 2018-03-06
ES2564677T3 (es) 2016-03-28
US20120148563A1 (en) 2012-06-14
EP2708239A1 (en) 2014-03-19
US9457069B2 (en) 2016-10-04
EP2470202A1 (en) 2012-07-04
SI2470202T1 (sl) 2014-02-28
RU2012110324A (ru) 2013-10-10
AU2010289969A1 (en) 2012-03-22
CN103816530A (zh) 2014-05-28
CY1114792T1 (el) 2016-12-14
DK2470202T3 (da) 2014-01-27

Similar Documents

Publication Publication Date Title
IN2012DN02210A (enExample)
MX366912B (es) Producción de vacuna recombinante en e. coli mediante conjugación enzimática.
MX2013008850A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
NZ709392A (en) Synergistic bacterial compositions and methods of production and use thereof
MX2011010930A (es) Modulacion de respuestas inflamatorias a través de factor xi.
WO2012047733A3 (en) Treatment of acne by conditioned media
EP4406593A3 (en) Use of long-acting glp-1 peptides
MX359854B (es) Anticuerpos anti-cxcr3.
UA115652C2 (uk) Сполука, що містить модифікований олігонуклеотид, комплементарна mir-21
PH12013501688A1 (en) Treatment of amyotrophic lateral sclerosis using umbilical derived cells
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
WO2013022740A3 (en) Gpr35 ligands and the uses thereof
TN2011000403A1 (en) Compositions and methods for extended therapy wiht aminopyridines
EP2579863A4 (en) COMPOUNDS FOR THE TREATMENT OF BOVINE MASTITIS
PH12016500136A1 (en) Positive allosteric modulators of nicotinic acetylcholine receptor
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
GB2523696A (en) Methods of differentiating stem cells by modulating miR-124
MX364528B (es) Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas.
PH12014500057A1 (en) Positive allosteric modulators of nicotinic acetylcholine receptor
UA103197C2 (uk) Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами
AU2012240388A8 (en) Treatment regimens
MX2012000203A (es) Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cancer.
WO2012112862A3 (en) Treating mycobacterial infection with cu+/++ boosting therapeutics
MX2014006990A (es) Tratamiento para diabetes tipo i y tipo ii.
WO2010121226A3 (en) Anticancer agents